Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Johnson & Johnson (JNJ) Worthy of Being in Your Portfolio?

Page 1 of 2

The SEC requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings discloses the funds’ positions on September 30. We at Insider Monkey have compiled an extensive database of more than 700 of those elite funds and prominent investors’ filings. In this article, we analyze how these elite funds and prominent investors traded Johnson & Johnson (NYSE:JNJ) based on those filings.

Hedge fund interest towards Johnson & Johnson (NYSE:JNJ) was flat at the end of last quarter. This is usually a negative indicator. At the end of this article we will also compare JNJ to other stocks including Facebook Inc (NASDAQ:FB), General Electric Company (NYSE:GE), and AT&T Inc. (NYSE:T) to get a better sense of its popularity.

Follow Johnson & Johnson (NYSE:JNJ)
Trade (NYSE:JNJ) Now!

At the moment there are tons of methods shareholders can use to analyze stocks. A couple of the most useful methods are hedge fund and insider trading interest. Our experts have shown that, historically, those who follow the top picks of the elite money managers can outpace their index-focused peers by a very impressive margin (see the details here).

care, pharmacist, business, pill, chemist, clinic, drugstore, medicine, illness, health, indoors, prescription, healthcare, pharmaceutical, medical, retail, drug, singapore, treatment, shelf, medication, hospital, store, shop, pharmacy

Trong Nguyen / Shutterstock.com

With all of this in mind, let’s take a glance at the key action regarding Johnson & Johnson (NYSE:JNJ).

What does the smart money think about Johnson & Johnson (NYSE:JNJ)?

At the end of the third quarter, a total of 82 of the hedge funds tracked by Insider Monkey were long this stock, unchanged over the quarter. With hedge funds’ sentiment swirling, there exists an “upper tier” of notable hedge fund managers who were increasing their holdings meaningfully (or already accumulated large positions).

jnj

According to Insider Monkey’s hedge fund database, Ken Fisher’s Fisher Asset Management has the biggest position in Johnson & Johnson (NYSE:JNJ), worth close to $1.28 billion, amounting to 2.3% of its total 13F portfolio. Sitting at the No. 2 spot is Yacktman Asset Management, led by Donald Yacktman, holding a $725.8 million position; the fund has 6.3% of its 13F portfolio invested in the stock. Remaining peers that hold long positions comprise Cliff Asness’s AQR Capital Management, Phill Gross and Robert Atchinson’s Adage Capital Management and Jim Simons’ Renaissance Technologies.

Page 1 of 2
Loading Comments...